Xuesong Han, PhD, on Medicaid Expansion and Receipt of Palliative Care Among Individuals Newly Diagnosed With Advanced-Stage Cancers

2022 ASCO Quality Care Symposium


Xuesong Han, PhD, of the American Cancer Society, discusses findings showing that among newly diagnosed patients with stage IV cancers, Medicaid expansion was associated with increases in receipt of palliative care, although overall usage was low. The increase varied by cancer type. Improving Medicaid coverage may facilitate access to guideline-based palliative care (Abstract 73).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Palliative care is a guideline based practice for cancer patients with advanced stage. However, the utilization has been low in the United States. In this study, we try to answer this study question whether Medicaid expansion, a major component of the Affordable Care Act, expanding Medicaid eligibility to every adult younger than 65 years with a family income up to 138% Federal poverty level was associated with the receipt of palliative care among cancer patients newly diagnosed with stage IV cancers. To answer this study question, we use the National Cancer Database, a nationwide hospital based cancer registry, capturing 70% of all new cancer cases in the US each year. We identify that our study sample of over 685,000 patients, aged 18 to 64 years, newly diagnosed with first primary stage IV cancers in 2010 through 2019 in 50 states from NCDB. We used a difference in differences approach comparing the changes in receipt of palliative care pre and post ACA in Medicaid expansion states. With the changes in non-expansion states, this indicating a net change associated with Medicaid expansion. Our results show that during the past decade, receipt of palliative care among stage IV cancer patients as part of their first line therapy had increased nationwide. However, the increase was greater in Medicaid expansion states. Specifically, the percent of the stage IV cancer patients who received the palliative care increased from 17% pre ACA to 18.9% post ACA in Medicaid expansion states, and increased from 15.7% to 16.7% in non-expansion states, translating to a net increase of 1.4 percentage points associated with Medicaid expansion. When we stratified by cancer type, we found that the increase was the strongest among the cancers of the lung, colorectal, oral cavity and the [inaudible 00:02:41], Non-Hodgkin's lymphoma, pancreas, and breast cancer among women. These are the most prevalent cancer types at stage IV, and often with a significant symptom burden. In summary, we found that Medicaid expansion was associated with increased receipt of palliative care among patients newly diagnosed with stage IV cancers, although the overall usage remained low. Our findings would suggest that Medicaid expansion can be a policy strategy to improve the guideline based palliative care. Our findings also pointed to a potentially widening geographic disparity in receiving palliative care because of differential state health policies in expanding Medicaid eligibility.

Related Videos

Issues in Oncology

Samyukta Mullangi, MD, MBA, on Predictors of Compliance With Payer-Led Oncology Clinical Pathways

Samyukta Mullangi, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses her findings showing that physicians’ prescribing behavior may be influenced by payer-led pathways. Pathway compliance was associated with higher medical costs during a 6-month baseline period but lower health-care utilization, as measured in hospitalizations and emergency department visits during that baseline period (Abstract 7).

Breast Cancer
Issues in Oncology

Regina Barragán-Carrillo, MD, on Breast Cancer Screening in the Transgender Population

Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread information, it could possibly reduce the health-care inequalities faced by this diverse group of patients (Abstract 71).

Health-Care Policy

Justin M. Barnes, MD, on Medicaid Expansion and Changes in Cancer Mortality Rates

Justin M. Barnes, MD, of the Washington University School of Medicine, discusses the ways in which Medicaid expansion under the Affordable Care Act seems to affect distant diagnoses and cancer deaths per year, the differences in the impact of expansion between Black and White patients in the United States, and why insurance alone appears to be insufficient to overcome structural barriers to care for some populations.

Symptom Management
Issues in Oncology

Dawn L. Hershman, MD, on Prophylactic Colony Stimulating Factors for Neutropenia: Improving Clinicians’ Prescribing Practices

Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention is a feature of pragmatic trials, careful prestudy planning to estimate nonadherence is critical to ensure adequate power to detect an effect. Understanding reasons for intervention opt-outs may also inform future pragmatic studies aimed at improving adherence to practice guidelines.

Issues in Oncology

Changchuan Jiang, MD, MPH, on Transportation Barriers, Delays in Cancer Care, and Increased Mortality for Patients With Cancer

Changchuan Jiang, MD, MPH, of Roswell Park Comprehensive Cancer Center, discusses the lack of transportation as a potentially modifiable barrier to care for patients with cancer. Timely intervention may reduce visits to hospital emergency departments, lower costs, and improve outcomes (Abstract 70).